{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:59:28Z","timestamp":1773295168811,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejmech.2024.117231","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T00:44:40Z","timestamp":1736037880000},"page":"117231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel 1H-indole-3-carbonitrile derivatives as potent TRK Inhibitors"],"prefix":"10.1016","volume":"285","author":[{"given":"Shaoshan","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengdi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengjian","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2951-0939","authenticated-orcid":false,"given":"Jinhua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117231_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02623703","article-title":"The nerve growth factor thirty-five years later","volume":"23","author":"Levi-Montalcini","year":"1987","journal-title":"Vitro Cell Dev Biol"},{"key":"10.1016\/j.ejmech.2024.117231_bib2","first-page":"115","article-title":"The TRK family of tyrosine protein kinase receptors","volume":"1072","author":"Barbacid","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2024.117231_bib3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","article-title":"Neurotrophins: roles in neuronal development and function","volume":"24","author":"Huang","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2024.117231_bib4","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1021\/jm030221q","article-title":"Molecular basis of neurotrophin-receptor interactions","volume":"46","author":"Pattarawarapan","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117231_bib5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/en.2002-221002","article-title":"The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins","volume":"144","author":"Ranzi","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2024.117231_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.117231_bib7","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/jclinpath-2018-205679","article-title":"Testing algorithm for identification of patients with TRK fusion cancer","volume":"72","author":"Penault-Llorca","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.ejmech.2024.117231_bib8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.117231_bib9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2024.117231_bib10","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.117231_bib11","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117231_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2024.117231_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.117231_bib14","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdw042","article-title":"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2024.117231_bib15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.117231_bib16","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent-front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.117231_bib17","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1021\/acs.jmedchem.3c01645","article-title":"Discovery, optimization, and evaluation of novel pyridin-2(1H)-one analogues as potent TRK inhibitors for cancer treatment","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117231_bib18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/ml200261d","article-title":"Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models","volume":"3","author":"Albaugh","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.117231_bib19","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1021\/acs.jmedchem.1c01597","article-title":"Structural optimization and structure-activity relationship studies of 6,6-dimethyl-4-(phenylamino)-6H-pyrimido[5,4-b][1,4]oxazin-7(8H)-one derivatives as a new class of potent inhibitors of pan-TRK and their drug-resistant mutants","volume":"65","author":"Pan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117231_bib20","doi-asserted-by":"crossref","first-page":"E297","DOI":"10.1073\/pnas.1611577114","article-title":"Structural characterization of nonactive site, TRKA-selective kinase inhibitors","volume":"114","author":"Su","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejmech.2024.117231_bib21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.bmcl.2003.12.002","article-title":"Discovery and in vitro evaluation of potent TRKA kinase inhibitors: oxindole and aza-oxindoles","volume":"14","author":"Wood","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2024.117231_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106563","article-title":"Discovery of novel phenyl triazole analogs as TRK\/ALK dual inhibitors with prospective antitumor effects","volume":"136","author":"Cao","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.117231_bib23","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ejmech.2019.07.019","article-title":"An insight into the medicinal perspective of synthetic analogs of indole: a review","volume":"180","author":"Garg","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117231_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103021","article-title":"Medicinal chemistry of indole derivatives: current to future therapeutic prospectives","volume":"89","author":"Kumari","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.117231_bib25","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1535-7163.MCT-16-0909","article-title":"Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers","volume":"16","author":"Fuse","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.117231_bib26","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1111\/cas.15354","article-title":"Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells","volume":"113","author":"Suzuki","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2024.117231_bib27","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1021\/acs.joc.2c03045","article-title":"Cascade oxidative trifluoromethylthiolation and cyclization of 3-alkyl-1-(2-(alkynyl)phenyl)indoles","volume":"88","author":"Uppalabat","year":"2023","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2024.117231_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105181","article-title":"N-(3-cyano-1H-indol-5-yl)isonicotinamide and N-(3-cyano-1H-indol-5-yl)-1H-benzo[d]imidazole-5-carboxamide derivatives: novel amide-based xanthine oxidase inhibitors","volume":"115","author":"Tu","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.117231_bib29","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/acs.orglett.3c01756","article-title":"N-heterocyclic carbene-catalyzed enantioselective synthesis of N-fused polycyclic dihydropyrido[1,2-\u03b1]-indolones","volume":"25","author":"Yao","year":"2023","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2024.117231_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114467","article-title":"Discovery of novel coumarin-indole derivatives as tubulin polymerization inhibitors with potent anti-gastric cancer activities","volume":"238","author":"Song","year":"2022","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424011139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424011139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T22:32:36Z","timestamp":1740349956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424011139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":30,"alternative-id":["S0223523424011139"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117231","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel 1H-indole-3-carbonitrile derivatives as potent TRK Inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117231"}}